Low serum double-stranded DNA levels are associated with higher survival rates in severe COPD patients.

IF 4.3 3区 医学 Q1 RESPIRATORY SYSTEM ERJ Open Research Pub Date : 2024-07-15 eCollection Date: 2024-07-01 DOI:10.1183/23120541.00240-2024
Sharyn A Roodenburg, Jorine E Hartman, Ilse A Eichhorn, Dirk-Jan Slebos, Simon D Pouwels
{"title":"Low serum double-stranded DNA levels are associated with higher survival rates in severe COPD patients.","authors":"Sharyn A Roodenburg, Jorine E Hartman, Ilse A Eichhorn, Dirk-Jan Slebos, Simon D Pouwels","doi":"10.1183/23120541.00240-2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Damage-associated molecular patterns (DAMPs) are endogenous danger signals that alert and activate the immune system upon cellular damage or death. It has previously been shown that DAMP release is increased in patients with COPD, leading to higher levels in extracellular fluids such as serum. In the current study we investigated whether the serum levels of DAMPs were associated with survival rates in COPD patients.</p><p><strong>Methods: </strong>A panel of seven DAMPs, consisting of HMGB1, fibrinogen, α-defensin, heat shock protein 70, S100A8, galectin-9 and double-stranded DNA (dsDNA), was measured in serum of 949 severe COPD patients. Maximally selected rank statistics was used to define cut-off values and a Cox proportional hazards model was used to evaluate the effect of high or low DAMP levels on 4-year survival. For DAMPs that were found to affect survival significantly, baseline characteristics were compared between the two DAMP groups.</p><p><strong>Results: </strong>Out of the seven DAMPs, only dsDNA was significantly associated with 4-year survival. Patients with elevated serum level of dsDNA had higher 4-year mortality rates, lower FEV<sub>1</sub> % predicted values and higher emphysema scores.</p><p><strong>Discussion: </strong>In conclusion, in a clinical cohort of 949 patients with moderate-to-severe COPD, elevated serum levels of dsDNA were associated with a higher risk of death. This study further illustrates the potential role of circulating DAMPs, such as dsDNA, in the progression of COPD. Together, the results of this study suggest that levels of circulating dsDNA might serve as an additional prognostic biomarker for survival in COPD patients.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 4","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247366/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/23120541.00240-2024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Damage-associated molecular patterns (DAMPs) are endogenous danger signals that alert and activate the immune system upon cellular damage or death. It has previously been shown that DAMP release is increased in patients with COPD, leading to higher levels in extracellular fluids such as serum. In the current study we investigated whether the serum levels of DAMPs were associated with survival rates in COPD patients.

Methods: A panel of seven DAMPs, consisting of HMGB1, fibrinogen, α-defensin, heat shock protein 70, S100A8, galectin-9 and double-stranded DNA (dsDNA), was measured in serum of 949 severe COPD patients. Maximally selected rank statistics was used to define cut-off values and a Cox proportional hazards model was used to evaluate the effect of high or low DAMP levels on 4-year survival. For DAMPs that were found to affect survival significantly, baseline characteristics were compared between the two DAMP groups.

Results: Out of the seven DAMPs, only dsDNA was significantly associated with 4-year survival. Patients with elevated serum level of dsDNA had higher 4-year mortality rates, lower FEV1 % predicted values and higher emphysema scores.

Discussion: In conclusion, in a clinical cohort of 949 patients with moderate-to-severe COPD, elevated serum levels of dsDNA were associated with a higher risk of death. This study further illustrates the potential role of circulating DAMPs, such as dsDNA, in the progression of COPD. Together, the results of this study suggest that levels of circulating dsDNA might serve as an additional prognostic biomarker for survival in COPD patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清双链 DNA 水平低与严重慢性阻塞性肺病患者的存活率较高有关。
引言损伤相关分子模式(DAMPs)是一种内源性危险信号,在细胞损伤或死亡时会发出警报并激活免疫系统。以前的研究表明,慢性阻塞性肺病患者体内的 DAMP 释放量增加,导致血清等细胞外液中的 DAMP 水平升高。在本研究中,我们调查了 DAMPs 的血清水平是否与 COPD 患者的存活率有关:方法:测量了 949 名重度 COPD 患者血清中的七种 DAMPs,包括 HMGB1、纤维蛋白原、α-防御素、热休克蛋白 70、S100A8、galectin-9 和双链 DNA(dsDNA)。采用最大选择秩统计法确定临界值,并采用 Cox 比例危险模型评估高或低 DAMP 水平对 4 年生存率的影响。对于发现对生存率有显著影响的 DAMPs,比较了两组 DAMPs 的基线特征:结果:在7种DAMP中,只有dsDNA与4年生存率有显著相关性。血清中dsDNA水平升高的患者4年死亡率更高,FEV1预测值更低,肺气肿评分更高:总之,在由 949 名中重度慢性阻塞性肺病患者组成的临床队列中,血清中 dsDNA 水平升高与较高的死亡风险有关。这项研究进一步说明了循环中的 DAMPs(如 dsDNA)在慢性阻塞性肺病的发展过程中的潜在作用。总之,本研究的结果表明,循环 dsDNA 水平可作为慢性阻塞性肺病患者生存的额外预后生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ERJ Open Research
ERJ Open Research Medicine-Pulmonary and Respiratory Medicine
CiteScore
6.20
自引率
4.30%
发文量
273
审稿时长
8 weeks
期刊介绍: ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.
期刊最新文献
Vascular involvement in idiopathic pulmonary fibrosis. Wearable technology for detection of COPD exacerbations: feasibility of the Health Patch. Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial. Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction. Erratum: "Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients". Kiki Waeijen-Smit, Mieke Crutsen, Spencer Keene, Marc Miravitlles, Ernesto Crisafulli, Antoni Torres, Christian Mueller, Philipp Schuetz, Thomas J. Ringbæk, Fabio Fabbian, Evgeni Mekov, Timothy H. Harries, Chung-tat Lun, Begum Ergan, Cristóbal Esteban, Jose M. Quintana Lopez, José Luis López-Campos, Catherina L. Chang, Robert J. Hancox, Eskandarain Shafuddin, Hollie Ellis, Christer Janson, Charlotte Suppli Ulrik, Gunnar Gudmundsson, Danny Epstein, José Dominguez, Alicia Lacoma, Christian Osadnik, Inmaculada Alia, Francesco Spannella, Zuhal Karakurt, Hossein Mehravaran, Cecile Utens, Martijn D. de Kruif, Fanny Wai San Ko, Samuel P. Trethewey, Alice M. Turner, Dragos Bumbacea, Patrick B. Murphy, Kristina Vermeersch, Shani Zilberman-Itskovich, John Steer, Carlos Echevarria, Stephen C. Bourke, Nicholas Lane, Jordi de Batlle, Roy T.M. Sprooten, Richard Russell, Paola Faverio, Jane L. Cross, Hendrik J. Prins, Martijn A. Spruit, Sami O. Simons, Sarah Houben-Wilke and Frits M.E. Franssen. ERJ Open Res 2024; 10: 00838-2023.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1